分组1 - Acadia Pharmaceuticals reported quarterly earnings of $0.20 per share, exceeding the Zacks Consensus Estimate of $0.16 per share, and showing a significant increase from $0.01 per share a year ago, representing an earnings surprise of 25% [1] - The company achieved revenues of $241.96 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 2.85%, and up from $165.24 million year-over-year [1] - Over the last four quarters, Acadia has surpassed consensus EPS estimates three times and has also topped consensus revenue estimates three times [1] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.13 on revenues of $251.11 million, while for the current fiscal year, the estimate is $0.58 on revenues of $952.88 million [4] - The Medical - Biomedical and Genetics industry, to which Acadia belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [5] - G1 Therapeutics, another company in the same industry, is expected to report a quarterly loss of $0.17 per share, reflecting a year-over-year change of -221.4%, with revenues anticipated to be $15.88 million, down 62.6% from the previous year [5][6]

Exhibit 99.1 Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview - Second quarter total net product sales of $242.0 million, up 46% year-over-year SAN DIEGO, CA, August 6, 2024 – Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the second quarter ended June 30, 2024. "In the second quarter of 2024, Acadia delivered $242.0 million in net product sales, highlighted by 11% year-over-year growth in NUPLAZID net sales and 11% sequential ...

The market expects Acadia Pharmaceuticals (ACAD) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to b ...

Acadia Pharmaceuticals (ACAD) is a commercial-stage company focused on developing innovative medicines to address unmet medical needs in central nervous system (CNS) disorders and rare diseases. ACAD’s commercial portfolio comprises two marketed drugs — Nuplazid (pimavanserin) and Daybue (trofinetide).Acadia’s first drug, Nuplazid, is the first and the only FDA-approved treatment for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis in the United States. Its second ...

ktsimage Shares of central nervous system therapy concern Acadia Pharmaceuticals, Inc. (NASDAQ:ACAD) have recently fallen to their lowest level since its second commercial asset, Daybue, was approved. The main impetus for the decline was the failure of its other commercial product (Nuplazid) in a Phase 3 label-expansion trial for negative symptoms of schizophrenia. With a potential gene therapy threat to Daybue in early-stage studies but trading at two times FY24E revenue net of cash, Acadia merited another ...

It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD) . Shares have added about 0.6% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Acadia due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Acadia Q1 Earnings Surpass Estimates, ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences: Citizens JMP Life Sciences Conference Fireside Chat: Tuesday, May 14, 2024 at 1:30 p.m. Eastern Time in New York, NY 2024 RBC Capital Markets Global Healthcare Conference Fireside Chat: Wednesday, May 15, 2024 at 11:30 a.m. Eastern Time in New York, NY BofA Securities Health Care Conference Fireside Chat: Wednesday, May 16, 2024 at 12:20 p.m. Eastern Time in ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences:Citizens JMP Life Sciences ConferenceFireside Chat: Tuesday, May 14, 2024 at 1:30 p.m. Eastern Time in New York, NY2024 RBC Capital Markets Global Healthcare ConferenceFireside Chat: Wednesday, May 15, 2024 at 11:30 a.m. Eastern Time in New York, NYBofA Securities Health Care ConferenceFireside Chat: Wednesday, May 16, 2024 at 12:20 p.m. Eastern Time in Las V ...

Acadia Pharmaceuticals Inc. (ACAD) reported first-quarter 2024 earnings of 10 cents per share, beating the Zacks Consensus Estimate of 4 cents. In the year-ago quarter, the company had incurred a loss of 27 cents per share.The bottom line improved year over year owing to higher product sales.Acadia recorded total revenues of $205.8 million, which missed the Zacks Consensus Estimate of $206.9 million. Acadia’s net product revenues comprise revenues generated from the sale of its two marketed products, Nuplaz ...

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Corporate Participants Al Kildani - Senior Vice President, Investor Relations and Corporate Communications Steve Davis - President and Chief Executive Officer Brendan Teehan - Chief Operating Officer, Head of Commercial Kimberly Manhard - Senior Vice President, Global Strategic Planning and Execution Mark Schneyer - Chief Financial Officer Conference Call Participants Tessa Romero - JPMorgan Ritu Baral - TD Co ...